REUBEN GOBEZIE, MD
Medical Practice at Orange Pl, Cleveland, OH

2007020, Sep 6, 2007

Dec 13, 2006

11/638254

Reuben Gobezie - Cleveland Heights OH, US
David Lee - Needham MA, US

C12Q 1/68, G01N 33/53, G06F 19/00

435006000, 435007100, 536023200, 702019000

The present invention relates to the identification and use of protein expression profiles with clinical relevance to osteoarthritis (OA). In particular, the invention provides the identity of marker proteins whose expressions are correlated with OA, OA subtype, and/or OA progression. Methods and kits are described for using these protein expression profiles in the study and/or diagnosis of OA, in the determination of the degree of advancement of OA, and in the selection and/or monitoring of treatment regimens. The invention also relates to the screening of drugs that modulate expression of these proteins or nucleic acid molecules encoding these proteins, in particular for the development of disease-modifying OA agents.

2010029, Nov 18, 2010

Jun 16, 2006

11/917661

Peter J. Millett - Edwards CO, US
David A. Sarracino - Andover MA, US
Bryan Krastins - Cambridge MA, US
Reuben Gobezie - Cleveland Heights OH, US

THE BRIGHAM AND WOMEN'S HOSPITAL, INC. - Boston MA

A61K 38/00, C07H 21/04, C40B 40/10, G01N 33/566, C12Q 1/68, G01N 33/573, G01N 33/53, C40B 30/04, A61P 19/02

514 168, 536 232, 536 235, 536 2431, 506 18, 436501, 435 71, 435 6, 435 74, 435 792, 506 9, 530300

The present invention relates to the identification and use of protein expression profiles with clinical relevance to osteoarthritis (OA). In particular, the invention provides the identity of marker proteins whose expression is correlated with OA and OA progression. Methods and kits are described for using these protein expression profiles in the study and/or diagnosis of OA, in the determination of the degree of advancement of OA, and in the selection and/or monitoring of treatment regimens. The invention also relates to the screening of drugs that modulate expression of these proteins or nucleic acid molecules encoding these proteins, in particular for the development of disease-modifying OA agents.

2012019, Jul 26, 2012

Jan 22, 2010

13/145796

Reuben Gobezie - Cleveland Heights OH, US
David M. Lee - Basel, CH

G01N 33/566, G01N 33/573

435 74, 436501

The present invention relates to the identification and use of protein expression profiles with clinical relevance to osteoarthritis. In particular, the invention provides the identity of marker proteins whose expressions are correlated with OA, and/or OA progression. Methods and kits are described for using these protein expression profiles in the study and/or diagnosis of OA, in the determination of the degree of advancement of OA, and in the selection and/or monitoring of treatment regimens. The invention also relates to the screening of drugs that modulate expression of these proteins or nucleic acid molecules encoding these proteins, in particular for the development of disease-modifying OA agents.

8372594, Feb 12, 2013

Jan 22, 2010

13/145795

David M. Lee - Basel, CH
Eric Boilard - Quebec, CA
Michael H. Gelb - Seattle WA, US
Reuben Gobezie - Cleveland Heights OH, US

Case Western Reserve University - Cleveland OH
Brigham and Womens Hospital - Boston MA
The University of Washington - Seattle WA

G01N 33/53, G01N 31/00

435 721, 435 71, 436 1, 436501, 436518, 424 91, 424520, 422 1, 422430, 530300, 530350

The present invention relates to the use of protein expression profiles of sPLA2 isoforms with clinical relevance to osteoarthritis (OA). In particular, the invention provides methods for diagnosing OA or determining risk factors for development of OA based on expression of sPLA2-IIA.